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Abstract
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industry characteristics. Firms that exhibit larger asset and cash holdings, higher profitability, and more
R&D investments are in general more innovative in terms of both quality and quantity. In post-IPO or postM&A years, higher industry sales concentration and geographic concentration tend to correlate with lower
innovation quantity and higher innovation quality. This paper also attempts to study the mobility of
innovative employees around IPO and M&A, but the results lack sufficient insights on whether the
observed post-event decline in innovation quality can be explained by changes in the composition of
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Abstract
This paper examines the changes in firms’ innovation performance around initial public
offerings (IPO) and mergers and acquisitions (M&A) using innovation data based on patent
applications, new product introductions, and scientific article publications. The quantity of
innovation is measured by number of innovative outputs and the quality of innovation is
measured by a variety of metrics including patent or article citation count and content-based
novelty score. Results generally show that innovation quantity increases while innovation quality
declines following IPO and M&A events. The findings are consistent among patent-based,
product-based, and publication-based metrics, and confirm with the results from previous
literature. In addition, innovation performance is found to vary with financial performance and
industry characteristics. Firms that exhibit larger asset and cash holdings, higher profitability,
and more R&D investments are in general more innovative in terms of both quality and quantity.
In post-IPO or post-M&A years, higher industry sales concentration and geographic
concentration tend to correlate with lower innovation quantity and higher innovation quality.
This paper also attempts to study the mobility of innovative employees around IPO and M&A,
but the results lack sufficient insights on whether the observed post-event decline in innovation
quality can be explained by changes in the composition of innovators. Overall, despite the ability
to produce more innovations after going public or acquiring another company, firms should be
mindful of the potential loss in innovation quality.

Keywords: innovation, IPO, M&A, industry characteristics, financial performance, innovator
mobility
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1. Introduction and Literature Review
The quality of innovation is essential to a firm’s long-term performance, as innovative
activities can not only enhance a firm’s competitiveness in the market, but also generate positive
externalities for the society through the introduction of new technologies. According to the U.S.
Department of Commerce (2007), innovation is “the design, invention, development and/or
implementation of new or altered products, services, processes, systems, organizational
structures, or business models for the purpose of creating new value for customers and financial
returns for the firm.” In other words, innovation needs to be both novel and commercially
valuable. Literature on firm innovation has suggested that innovation capability is the most
important determinant of firm performance and that higher innovativeness is related to better
firm performance in terms of return on investment and profitability (Calantone, Cavusgil, and
Zhao 2002). Despite the importance of innovation to corporate performance, it is oftentimes
difficult for firms to maintain innovation capability over time, especially after firms experience
substantial strategic changes such as initial public offerings (IPO) and mergers and acquisitions
(M&A). It is likely that IPO and M&A events will impact a firm’s innovation strategy and
thereafter lead to changes in innovation performance.

There has been a large amount of research that investigates how general firm
performance changes around IPO and M&A. Studies have shown that there is significant postIPO deterioration in firms’ operational and financial performance (Jain and Kini 1994). On the
M&A side, mixed views have emerged on whether post-M&A performance of the combined
firm improves or declines, with some scholars finding that long-term operational and financial
performance of M&A activities depend on various factors such as size of the target firm and
incentive compensation plans (Ramaswamy and Waegelein 2003).
5

It wasn’t until recently that researchers have started to specifically link innovation, the
most crucial driver of firm performance, with IPO and M&A events. While firms invest in
innovation primarily through research and development (R&D) expenditures, many scholars
have illustrated that R&D is not a reliable measure of innovation, as R&D only captures one
observable input of innovation and does not account for other observable and unobservable
aspects such as talent allocation and incentive compensation plans (He and Tian 2013). The most
popular measure of innovation among scholars is patent information. Patent-based metrics are
found to be more economically meaningful than R&D as they not only convey the strength of a
firm’s intellectual property but also provide insights into the firm’s market value (Hall, Jaffe, and
Trajtenberg 2005; Bernstein 2015). Scholars who utilize patent data in general find that the
quality of innovation, as measured by the number of patent citations, tends to decrease following
IPO activities due to short-termism – the pressures from shareholders to increase short-term
earnings (Bernstein 2015; He and Tian 2013). In terms of innovation strategy, private firms tend
to be more exploratory and rely more on existing knowledge while public firms are more
exploitative and more likely to invest in new technologies (Gao, Hsu, and Li 2018). In terms of
M&A, scholars have also applied patent-based metrics to explore the relationship between
innovative activities and M&A considerations and discovered that post-merger innovation
performance increases when there is a reasonable pre-M&A overlap between the technologies of
the acquirer firm and those of the target firm (Bena and Li 2014; Cloodt, Hagedoorn, and
Kranenburg 2006). One study also concludes that the quality of firm innovation is highest under
private ownership, intermediate under M&A, and lowest under public ownership, based on
patent data of VC-backed biotech firms (Aggarwal and Hsu 2013).
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While there is already a moderate amount of research on the relationship between
innovation performance and strategic activities in recent years, most of existing literature uses
patent data as a proxy for innovation. Although scholars have illustrated the reliability of patentbased measurement of innovation (Hall, Jaffe, and Trajtenberg 2005; Bernstein 2015), this
practice may still lack sufficient content validity as patenting is only one way to create
innovation. Firms may also choose to innovate through academic publications, new product
introductions, as well as other activities that are not patented or have not been patented yet.
Several studies have adopted measures other than patent data to analyze firm innovation
performance. Murray and Stern (2007) discover that innovation leads to both scientific
publications and patent grants, with publications pre-dating patent grants and publication
citations declining following patent grants. Moreover, Wies and Moorman (2015) measure firm
innovation using new product introductions and find that public firms in the consumer-packaged
goods industry show increased innovation level but decreased innovation riskiness compared to
private firms. Despite the variety of innovation measures, application of simply one particular
metric may still fail to provide a comprehensive image of a firm’s innovation performance.

In addition to the lack of content validity in selecting proxy for innovation, most of the
existing research also takes a very broad approach to assess innovation performance, which
speaks to quantity of innovation and quality of innovation. While quantity can be measured in a
straightforward way through counting the number of innovation outputs, the quality or degree of
novelty of each innovation is harder to operationalize. The existing literature has largely used the
number of citations a patent receives to measure innovation quality. According to Bernstein
(2015), the citation count metric is capable of distinguishing between breakthrough innovation
and incremental innovation as it reflects the importance other inventors place on the particular
7

patent. However, citation count may not provide sufficient criterion validity since this metric
only reflects the number of times an innovation is cited without looking into the specific content
of the innovation output. It is possible that inventors from other firms are not citing the core idea
in the patent, or that the patent is contributing an incremental idea to an existing field rather than
putting forward a breakthrough idea.

2. Research Question and Hypotheses
This paper aims to contribute to existing literature on firm-level innovation performance
and how it relates to strategic decisions. I intend to address the lack of content and criterion
validity in innovation measurement by examining various innovation modes and innovation
metrics to present a more thorough analysis of firm innovation performance. I study three modes
of innovation – patent applications, new product introductions, and scientific publications – and
explore how each innovation mode relates to IPO and/or M&A activities. When selecting metrics
to measure the quantity and quality of innovation, in addition to the traditional metrics such as
number of innovation outputs and number of citations, I also use other metrics that are derived
from the specific content of each innovation output. Text mining of innovative content should
allow for a more in-depth examination of innovation quality than simply counting the number of
citations. For example, in analyzing scientific publications data, I assign an innovation novelty
score for each published scientific article through calculating the average age of non-stop words
in the abstract of the article.

This paper also attempts to explore possible reasons behind changes in innovation
performance around IPO and M&A activities. While shareholder pressure for short-term
earnings is widely regarded by the literature as a key reason for lower innovation quality of
8

public firms (Bernstein 2015; He and Tian 2013; Asker, Farre-Mensa, and Ljungqvist 2014),
innovator mobility may also explain this phenomenon as innovators are the main employees
responsible for producing innovation output and they may leave or stay following the firm’s
strategic initiatives due to changes in organizational culture and incentive compensation plans
(Bernstein 2015). This paper focuses on exploring the mobility of scientific publication authors
around IPO and M&A activities. Additionally, innovation dynamics can also vary across
industries due to the impact of different structural forces and differ across firms that exhibit
distinct levels of financial performance. Thus, industry characteristics (sales concentration,
turbulence or instability, geographic concentration) and financial metrics (total assets, net
income, cash, R&D investments) are also examined as potential factors that may affect
innovation performance around strategic activities.

3. Datasets
There are two pillars of data used in this paper. The first pillar includes data on firm-level
innovative activities. Three categories of innovation data will be examined: patent applications,
new product introductions, and scientific publications. The second pillar of data in the paper is
firm-level strategic and financial information, including IPO and M&A dates and financial
metrics.

A. Patent Data
Raw patent data is obtained from the patent database of the National Bureau of Economic
Research (NBER), which contains more than three million patents filed to the United States
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Patent and Trademark Office (USPTO) from 1976 to 2006 (Hall, Jaffe, and Trajtenberg 2001).
The database is publicly available and includes the patents filed by each firm to USPTO as well
as the number of citations, originality metric, and generality metric of each patent. The NBER
database also contains matching of firm names in the USPTO database with GVKEY (a unique
firm identifier) used by the Compustat financial information database so that I can match each
firm’s patent applications with its IPO status and other financial metrics.

B. Product Introductions Data
Data for new product introductions is gathered from the FactSet Revere database
available on Wharton Research Data Services (WRDS). The dataset houses information on new
product launches of all firms covered by FactSet since 2003. In addition to the dates of the firms’
product launches, the database also contains each product’s sector description as well as CUSIP
firm identifiers for matching to the Compustat database.

C. Scientific Publications Data
Data for scientific publications is obtained from the Elsevier's Scopus database, which is
the largest abstract and citation database of peer-reviewed literature. For each firm in my patent
universe that is also included by Scopus, I collect basic publication information, such as topic
and year, citation frequency, and author affiliations, as well as full abstracts of all articles
published by the firm. Because Scopus does not contain unique identifiers for firm names, I input
firm names into Scopus’ web search query to download basic publication information and then
match the firm names in the downloaded data to GVKEY identifiers. Article abstracts are
downloaded from a combination of Scopus web searches and Scopus Abstract Retrieval API. I
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use PyScopus, a Python wrapper for Scopus API developed by Zuo, Zhao, and Eichmann (2017),
and employ the Abstract Retrieval API to obtain abstracts by Scopus ID, which is a unique
article identifier.

For both product introductions and scientific publications data, I focus on firms that
overlap with my patent universe so that I can compare the analytical results from product-based
and publication-based metrics with those from patent-based metrics.

D. Firm-Level Strategic and Financial Information
Most of the data on firm-level strategic and financial information comes from the
Compustat North America database available on WRDS. Compustat contains U.S. and Canadian
fundamental information of both active and inactive publicly-traded companies since 1950. For
IPO events, I gather data items including IPO year, industry classification, and financial metrics
of all firms in my universe from Compustat. Industry classification is indicated by the Standard
Industry Classification (SIC) code which is a widely-used system for classifying firms into
industry areas. Firm financial metrics include natural logarithm of total assets (Log Total
Assets), ratio of R&D to total assets (R&D / Total Assets), ratio of net income to total assets (Net
Income / Total Assets), and ratio of cash to total assets (Cash / Total Assets). Then, I combine
data from each of the three innovation categories with IPO years, industry codes, and financial
metrics.
For M&A events, I use the Thomson Reuters SDC database on WRDS which houses
information on M&A transactions of public firms since 1965. To construct a relevant sample of
M&A transactions, I follow the sample selection treatment by Bena and Li (2014). I include an
M&A transaction only if the acquirer is seeking to own more than 50% of the target firm and
11

owns at least 90% of the target firm after deal completion. In addition, the target firm's total
assets must be valued at more than $1 million and neither the acquirer nor the target firm is a
financial institution. Then, I combine data from each innovation category with M&A years,
industry codes, and financial metrics.

4. Research Methodology and Results
My analysis mainly consists of two parts. I first run a series of Ordinary Least Squares
(OLS) linear regression analyses on the relationship between innovation performance and IPO or
M&A status based on patent data, product introductions data, and scientific publications data,
respectively. Following Bernstein (2015), I consider innovation performance from three years
before (-3) to five years after (+5) IPO or M&A events. I also control for industry characteristics
and financial metrics that may relate to change in innovation performance around IPO and M&A
events. The variables for industry characteristics include sales concentration, market turbulence,
and geographic concentration, and the variables for financial metrics include natural logarithm of
total assets, ratio of R&D to total assets, ratio of net income to total assets, and ratio of cash to
total assets. After examining the relationship between innovation performance and IPO or M&A
status, I explore innovator mobility around IPO and M&A activities based on author information
of firms’ scientific publications in order to analyze whether innovator mobility could be a
potential reason for the observed innovation changes around strategic events.

A. Changes in Innovation around IPO and M&A Events

12

i.

Changes in innovation around IPO based on patent metrics
Following Bernstein (2015), I first explore the relationship between patent-based

innovation metrics and IPO activities. Table 1 in the Appendix shows summary statistics for the
patent applications of firms from three years before to five years after IPO events. My dataset
includes 2,409 firms and 90,338 patent-firm-year observations. Patent applications are
concentrated in Computers and Communication, Drugs and Medicine, and Electronics industries.
Moreover, the mean number of patents increased for firms after they went public, but the mean
number of citations decreased. This seems to confirm with Bernstein (2015) that firms engaged
in higher number of innovations after IPO but the quality of innovation decreases.

For dependent variables, I use various patent-based metrics for innovation performance.
Innovation quantity is measured by patent count (number of patents of each firm). Innovation
quality is measured in three ways: citation count (number of times each patent is cited),
generality (degree to which a patent is cited by patents from a more diverse range of technology
classes), and originality (degree to which a patent is citing a broader set of technology classes).
In order to mitigate skewness in the distribution of patent and citation counts, we use the natural
logarithm of patent counts and the natural logarithm of citations counts. To avoid any zero
values, I add one to the patent count or citation count when taking the natural logarithm.

The primary independent variable is IPO status, which is a dummy variable that goes
from -3 to +5, representing 3 years before to 5 years after an IPO event. The coefficients for the
dummy variables are with respect to the year of IPO (year 0). I also include industry sales
concentration, industry turbulence, and industry geographic concentration which may also relate
to innovation performance. Industry sales concentration is measured by the Herfindahl-
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Hirschman index (HHI), which is the sum of squared market shares of all firms in an industry in
a year. In order to ensure that my industry classification is neither too broad nor too narrow in
the calculation of HHI, I use three-digit SIC codes. The universe of an entire industry is the set of
all firms belonging to the three-digit SIC code classification in the Compustat North America
database. In order to calculate the total sales of each three-digit-SIC industry in a specific year, I
ignore differences between fiscal year and calendar year and assume that each firm generated the
reported sales amount in the calendar year. Industry turbulence is calculated according to
Matraves and Rondi (2007), who measure the instability of the market share of the top five firms
in each industry over time. Geographic concentration of an industry is calculated using the EGI
index based on Dumais, Ellison, and Glaeser (2002) who measure the degree to which an
industry is geographically concentrated based on the state-level location of firms in the industry.
While Dumais, Ellison, and Glaeser (2002) measure industry market share using employment
data, I substitute sales revenue for employment. The formulas for the calculation of the three
industry metrics are as follows.
2
𝐻𝐻𝐼 = ∑𝑁
𝑖=1 𝑠𝑖 , where si is the sales market share of firm i in the three-digit-SIC

industry and N is the total number of firms within that industry.

𝑇𝑢𝑟𝑏𝑢𝑙𝑒𝑛𝑐𝑒 = 1 −

𝑂𝑡+1
𝑁𝑡+1

. I first identify the top 5 firms in each industry in

terms of sales revenue at time 𝑡, then 𝑂𝑡+1 is the cumulative squared market
shares of the same old 5 firms at time 𝑡 + 1, and 𝑁𝑡+1 is the cumulative squared
market shares of the actual top 5 firms at time 𝑡 + 1.
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𝐸𝐺𝐼 =

2 )−𝐻𝐻𝐼
𝐺𝑖𝑡 /(1−∑𝑠 𝑠𝑠𝑡

1−𝐻𝐻𝐼

, where 𝑠𝑖𝑠𝑡 is the share of industry 𝑖’s time 𝑡 sales in state

𝑠; 𝑠𝑠𝑡 is the state’s share of sales in the average industry; 𝐺𝑖𝑡 is the sum of squared
deviations of 𝑠𝑖𝑠𝑡 from 𝑠𝑠𝑡 ; and 𝐻𝐻𝐼 is the Herfindahl-Hirschman index.

In addition to industry characteristics, I also incorporate firm financial metrics, including
natural logarithm of total assets (Log Total Assets), ratio of R&D to total assets (R&D / Total
Assets), ratio of net income to total assets (Net Income / Total Assets), and ratio of cash to total
assets (Cash / Total Assets).

Based on these dependent and independent variables, I conduct regression analyses with
firm and year fixed effects to study how patent-based metrics evolve from -3 to +5 years around
IPO events. As such, the OLS equation I use is as follows:
8

𝑌𝑖 = 𝛽0 + ∑ 𝛽𝑛 𝐼𝑃𝑂_𝑆𝑡𝑎𝑡𝑢𝑠𝑖 + 𝛽9 𝐻𝐻𝐼𝑖 + 𝛽10 𝑇𝑢𝑟𝑏𝑢𝑙𝑒𝑛𝑐𝑒𝑖 + 𝛽11 𝐸𝐺𝐼𝑖
𝑛=1

+ 𝛽12 𝐿𝑜𝑔_𝑡𝑜𝑡𝑎𝑙_𝑎𝑠𝑠𝑒𝑡𝑠𝑖 + 𝛽13 𝑁𝑒𝑡_𝑖𝑛𝑐𝑜𝑚𝑒_𝑡𝑜_𝑡𝑜𝑡𝑎𝑙_𝑎𝑠𝑠𝑒𝑡𝑠𝑖
+ 𝛽14 𝐶𝑎𝑠ℎ_𝑡𝑜_𝑡𝑜𝑡𝑎𝑙_𝑎𝑠𝑠𝑒𝑡𝑠𝑖 + 𝛽15 𝑅&𝐷_𝑡𝑜_𝑡𝑜𝑡𝑎𝑙_𝑎𝑠𝑠𝑒𝑡𝑠𝑖
+ 𝛽16 (𝐼𝑃𝑂𝑖𝑃𝑜𝑠𝑡 ∗ 𝐻𝐻𝐼𝑖 ) + 𝛽17 (𝐼𝑃𝑂𝑖𝑃𝑜𝑠𝑡 ∗ 𝑇𝑢𝑟𝑏𝑢𝑙𝑒𝑛𝑐𝑒𝑖 )
+ 𝛽18 (𝐼𝑃𝑂𝑖𝑃𝑜𝑠𝑡 ∗ 𝑇𝑢𝑟𝑏𝑢𝑙𝑒𝑛𝑐𝑒𝑖 ) + 𝜀𝑖
𝑌 represents the innovation performance metric, and 𝐼𝑃𝑂_𝑆𝑡𝑎𝑡𝑢𝑠 is a dummy variable
showing the firm’s status with respect to its IPO year (𝐼𝑃𝑂 − 3 means the firm is three years
ahead of its IPO year). 𝐼𝑃𝑂𝑖𝑃𝑜𝑠𝑡 is equal to 1 if the firm is already past its IPO year, and
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𝐼𝑃𝑂𝑖𝑃𝑜𝑠𝑡 ∗ 𝐻𝐻𝐼𝑖 represents the interaction between HHI and post-IPO status. The same notation
applies to 𝐼𝑃𝑂𝑖𝑃𝑜𝑠𝑡 ∗ 𝑇𝑢𝑟𝑏𝑢𝑙𝑒𝑛𝑐𝑒𝑖 and 𝐼𝑃𝑂𝑖𝑃𝑜𝑠𝑡 ∗ 𝐸𝐺𝐼𝑖 .
Results:
Table 2 of the Appendix shows my analysis on the firm-level change in patent count
around IPO events, and Table 3 shows the firm-level change in three patent quality metrics –
average citation count, average generality, and average originality. As shown in Columns (1) and
(2) of Table 2 and Column (1) of Table 3, innovation in post-IPO years is characterized by
significantly higher quantity of patents produced but significantly lower citation count.
Nevertheless, as shown in Columns (2) and (3) of Table 3, most of the coefficients for generality
and originality metrics are not statistically significant, and the coefficient values do not show a
consistent pattern as the firm goes from private to public status. In terms of industry
characteristics, I observe that in post-IPO status, industry sales concentration, turbulence, and
geographic concentration are in general negatively related to patent count while positively
related to patent quality metrics.

In addition, as shown in Column (3) of Table 2, I also conduct another regression
analysis on patent count by adding four financial metrics variables: natural log of total assets,
ratio of net income to total assets, ratio of cash to total assets, and ratio of R&D expenditure to
total assets. The addition of these four independent variables to the regression disrupts the
increasing trend on patent count with respect to IPO status. Nevertheless, the results suggest that
firms with higher total assets, higher cash relative to assets, and higher R&D expenditure relative
to assets tend to produce more innovation outputs. This corresponds to the common consensus
that firms with more resources tend to have more capacity for innovation.
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ii.

Changes in innovation around M&A based on patent metrics
Next, I proceed to analyze the change in innovation performance around M&A events. I

have only considered the innovation performance of acquirer firms, as most target firms would
disappear following an acquisition. However, some target firms may remain as separate
subsidiaries of their corresponding acquirer firms after acquisitions, so some patents may be
assigned to the target firm rather than to the acquirer firm, despite the fact that the innovation
comes from the acquirer firm as a whole. As such, this analysis may underestimate the
innovation output following M&A events. Nevertheless, simply adding the patents assigned to
post-acquisition target firms to the patent set of the parent firms would not work as the Thomson
SDC database only contains M&A transactions involving public firms. Some public parent firms
may have acquired private subsidiary firms that operate as a standalone entity in the US patent
system and do not show up in the patent database.

My patent-M&A dataset contains 1,462 firms, 2,841 unique M&A transactions, and
473,023 unique patents. Table 4 in the Appendix exhibits summary statistics of patent
applications from three years before to five years after M&A transactions. Similar to the patentIPO dataset, the Computer and Electronics sectors appear to have the greatest number of patents.
In addition, the mean number of patents increases in post-M&A years, although the patent count
data seem to be highly skewed. On the other hand, the average number of patent citations
decreases following M&A.

Results:

I conduct regression analyses with firm and year fixed effects to study how patent-based
metrics evolve from -3 to +5 years with respect to M&A events. Table 5 of the Appendix shows
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the change in patent count around M&A events of acquirer firms, and Table 6 shows the change
in three patent quality metrics – average citation count, average generality, and average
originality. I obtain similar results as in the IPO case. Innovation in post-M&A years for acquirer
firms is characterized by higher quantity of patents produced (not significant) but significantly
lower citation count. In post-M&A years, industry sales concentration is in general negatively
related to patent count and positively related to patent quality metrics. Moreover, as observed in
Column (3) of Table 5, higher values of total assets, cash capacity, and R&D expenditure
correspond significantly to higher patent count.

iii.

Changes in innovation around M&A based on product introduction metrics
Using the same method as in the patent case, I explore the relationship between changes

in innovation performance and strategic activities based on the product introductions of firms.
Because the FactSet Revere database primarily covers public firms, there is very limited data on
the product introductions in the years before the firms went public. As a result, the analysis on
the innovation changes from three years before to five years after IPO is not robust enough. I
have decided to remove the analysis on product introductions for the case of IPO.

Table 7 in the Appendix displays summary statistics of the product introductions of firms
from three years before to five years after M&A events. The dataset contains 1,222 firms, 2,652
unique M&A deals, and 72,687 unique product launches. Product launches are concentrated in
Technology, Healthcare, and Consumer sectors. In addition, I observe that the average number of
total product introductions is higher while the average number of breakthrough introductions is
lower during the five years after M&A than during the three years before M&A.
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The dependent variable for the quantity of product-based innovation is total product
count (number of product launches). Since there is no equivalent of citation count for product
launches, I follow Wies and Moorman (2015) to calculate breakthrough product count in order to
measure the quality of product innovation. Since the FactSet Revere product database includes
sector specification of each product, I have assigned each product launch to either breakthrough
(product belonging to a new sector which the associated firm has never been in before) or reuse
(product belonging to a sector that applies to previous products of the associated firm). As a
result, the breakthrough product count is the number of breakthrough innovations by a firm each
year, effectively acting as a measure of innovation quality. Similar to the analysis of patent-based
metrics, the primary independent variable is M&A status (-3 to +5 years with respect to M&A
events). Industry metrics and financial metrics are also included as controlling variables. Then, I
run OLS linear regression analyses on the product introduction metrics against the independent
and control variables with firm and year fixed effects.

Results:
Table 8 of the Appendix shows the changes in number of product introductions around
M&A events. My results in general confirm with those derived from patent data. The coefficients
for total product innovation in post-M&A years are generally not significant, but the coefficient
values tend to be larger for post-M&A years, suggesting higher quantity of innovation compared
to pre-M&A years. The change in breakthrough or novel innovation around M&A is shown in
Table 9. The coefficient values for M&A status show a decreasing trend from three years before
to five years after M&A, suggesting that the number of breakthrough innovations is significantly
lower post-M&A compared to pre-M&A years. Therefore, this analysis confirms with patent-
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based results that innovation quantity tends to increase while quality tends to decline following
M&A events.

In addition, higher total assets and higher R&D expenditure relative to assets are
associated with higher number of product introductions, suggesting that firms with more
resources and more R&D investments tend to produce more innovations. In post-M&A years, all
of the three industry metrics (sales concentration, turbulence, and geographic concentration) are
in general negatively related to both total product introductions and breakthrough introductions.

iv.

Changes in innovation around IPO based on scientific publication metrics
In this section, I explore the relationship between innovation performance and strategic

activities based on the scientific publications of firms. For dependent variables, innovation
quantity is measured by article count (number of articles published by a firm in a year), and
innovation quality is measured in two ways – citation count (number of times each article is
cited) and novelty score.

The novelty score is calculated based on text mining of the abstract of each published
scientific article. Following Wu, Lou, and Hitt (2019), I employ a bag-of-words model to
identify non-stop words in the abstract of each article and calculate the age of each word by
journal field. I first clean up my collection of words by removing punctuations, numbers, and
stop words identified from the SMART stop-word list built into R’s text mining package. I then
reduce my “bag” so that it only includes the words appearing at least 1% of the time. Table 10
shows summary charts from text mining of the abstracts.
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To calculate word age, I follow the method of Wu, Lou, and Hitt (2019) and define that a
word has an age of zero on its first appearance in a particular journal field. If a word has
appeared previously, then the word age is the difference between application date of the article
and the time the word first appears. Based on the bag-of-word model, an article’s novelty score
would be based on the average age of all non-stop words in the abstract. In order to avoid cases
in which the age is zero, I add one to the age value. To obtain the novelty score of each article, I
calculate the reciprocal of the scaled age of all non-stop words in the abstract and take the
average of the reciprocal values as shown below. A firm’s novelty score is the average score of
the entire set of its published articles in a given year.
𝑁

1
1
𝑁𝑜𝑣𝑒𝑙𝑡𝑦 = ∑
𝑁
𝐴𝑔𝑒𝑤 + 1
𝑤=1

Table 11 shows the summary statistics of scientific publications of firms from three years
before to five years after IPO events. My dataset contains 786 unique firms and 6,603 unique
publications (2,135 with abstracts available). The publications are concentrated in Biology,
Engineering, and Medicine fields. The average publication count in post-IPO years is higher than
in pre-IPO years, while both the citation count and the abstract novelty score in post-IPO years
are lower than the pre-IPO case.

The primary independent variable is IPO status, which is a dummy variable that goes
from -3 to +5, representing 3 years before to 5 years after an IPO event. Industry and financial
metrics are also included as controlling variables. Then, I run OLS linear regression analyses on
the scientific publication metrics against the independent variables with firm and year fixed
effects.
21

Results:

As shown in Table 12, innovation quantity (as measured by number of scientific article
publications) in post-IPO years tends to be higher than in pre-IPO years, suggesting higher
quantity of innovation post-IPO. Table 13 exhibits the change in the number of research
collaborators, or article co-authors, around IPO and shows that the number of collaborators is
significantly higher in post-IPO years than in pre-IPO years. This indicates that the increase in
innovation quantity following an IPO process might be partially due to the increase in access to
research collaborators and resources for firms.

To examine the quality of innovation, I first look at the change in article citation count
around IPO. As shown in Table 14, however, this analysis does not generate significant results,
and the coefficient values from three years before to five years after IPO do not show a
consistent pattern. In order to better examine innovation quality, I use the novelty score
calculated from text mining of the abstracts of each article. Table 15 exhibits the change in firmlevel average novelty score around IPO. Similar to the citation count analysis based on patent
data, the novelty scores in post-IPO years are significantly lower than those in pre-IPO years. In
addition, in post-IPO status, industry metrics including sales concentration, turbulence, and
geographic concentration correlate positively with the novelty score, although the coefficients
lack significance.
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v.

Changes in innovation around M&A based on scientific publication metrics
I repeat the publication-based OLS regression analysis for the M&A case. The dependent

variables include publication count, collaborator count, average citation count, and average
novelty score. The primary independent variable is M&A status, which is a dummy variable that
goes from -3 to +5, representing 3 years before to 5 years after an M&A event. Industry and
financial metrics are also included as controlling variables.

My publication-M&A dataset contains 267 firms, 488 unique M&A transactions, and
5,215 unique publications (3,797 with abstracts available). Table 16 in the Appendix exhibits
summary statistics of scientific publications from three years before to five years after M&A
transactions. The Biology, Engineering, and Computer Science sectors appear to have the
greatest number of publications. In addition, the mean number of published articles is higher in
post-M&A years compared to pre-M&A years. While the mean novelty score decreases in postM&A years, the average number of publication citations increases following M&A.

Results:

As shown in Table 17, results for innovation quantity (as measured by number of
publications) are not significant but coefficient values do point to higher publication count in
post-M&A years. Similar to the IPO case, firms tend to have more research collaborators postM&A, as exhibited in Table 18.

I then proceed to analyze the change in article citation count around M&A and the
regression results are shown in Table 19. Contrary to previous findings on innovation quality
measured by citation count, the coefficient values for the average citation point to higher
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innovation quality in post-M&A years, although most results are insignificant. Nevertheless,
when the abstract novelty score is examined in Table 20, I find that the novelty score decreases
following M&A transactions, and this is consistent with previous findings that innovation quality
declines post-M&A. In addition, industry sales concentration and geographic concentration have
significantly positive correlations with the novelty score in post-M&A status. All four financial
metrics, including log total assets, net income to total assets, cash to total assets, R&D to total
assets correlate positively with the novelty score despite the coefficients lacking significance,
suggesting that firms with more competent resources, deployable capital, and R&D investments
may show higher innovation quality.

B. Innovator Mobility around IPO and M&A Events
The series of OLS regression analysis discussed in part A generally show that innovation
quantity increases while innovation quality decreases following IPO and M&A activities. The
findings are consistent among patent-based, product-based, and publication-based metrics. In
order to explain why innovation performance experiences these observed changes around IPO
and M&A activities, I focus on analyzing innovator mobility as a potential reason. According to
Bernstein (2015), key inventors may choose to leave or stay following an IPO or M&A event
due to changes in organizational culture and incentive compensation plans.

Following Bernstein (2015) who analyzes innovator mobility based on patent data, I
utilize the Scopus database to examine the mobility of the authors of firms’ scientific
publications. Since Scopus provides unique author identifiers, the authors can be classified into
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three types. A “stayer” is defined as an author with at least a single paper before and after the
IPO/M&A at the same firm; a “leaver” is defined as an author with at least a single paper at a
sample firm before the IPO/M&A, and at least a single paper in a different company after the
IPO/M&A; and a newcomer is defined as an author that has at least a single paper after the
IPO/M&A event at a sample firm, but no papers before, and has at least a single paper at a
different firm before the event. I attribute a publication equally to each author of the paper and
compare the behavior of stayers, leavers, and newcomers from 3 years before to 5 years after
IPO and M&A activities.

i.

Innovator mobility around IPO
To explore the innovator mobility around IPO, I compare the innovation performance of

stayers versus leavers during the three years before the IPO event, and the innovation
performance of stayers versus newcomers during the five years after IPO. As shown in Table 21,
the mean log publication count is used to compare the author-level innovation quantity, and the
mean log citation and mean novelty score are used to compare the author-level innovation
quality. The orange bars overlaid on the charts for each metric are error bars. For the author
types to differ significantly in each innovation metric on average, the error bars must have no
overlap.

According to the charts in Table 21, stayers produce significantly more publications on
average than leavers in pre-IPO years and significantly more publications on average than
newcomers in post-IPO years. However, the quality of innovations produced by stayers, leavers,
and newcomers is generally not significantly different, though newcomers on average produce
publications with significantly higher citations than stayers. As a result, we may infer that the
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increase in innovation quantity following IPO events might be partially explained by the ability
of stayers to publish more articles post-IPO. However, we do not have sufficient evidence to
propose that the post-IPO decline in firm-level innovation quality can be explained by the
mobility of authors.

ii.

Innovator mobility around M&A
I employ the same method on the publication-M&A dataset. As shown in Table 22, I

compare the innovation performance of stayers versus leavers during the three years before the
M&A event, and the innovation performance of stayers versus newcomers during the five years
after M&A. I observe that stayers produce significantly more publications on average than
leavers in pre-M&A years and significantly more publications on average than newcomers in
post-M&A years.

Measured by citation count, the quality of innovations produced by stayers is
significantly lower than that of leavers in pre-M&A years and significantly lower than that of
newcomers in post-M&A years. Measured by abstract novelty score, however, the quality of
innovations produced by stayers is significantly higher than that of leavers in pre-M&A years but
does not differ significantly from that of newcomers in post-M&A years.

Therefore, the increase in innovation quantity following M&A events might also come
from the higher number of innovations produced by stayers. For innovation quality, my results
are contradictory. For example, stayers produce innovations with lower mean citation count but
higher novelty score compared with leavers in pre-M&A years. As such, we are unable to obtain
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consistent findings to show that the observed changes in firm-level innovation quality can result
from author mobility.

C. Case Studies on Innovation Novelty of Selected Firms around IPO and M&A
Events
According to the previous analyses based on abstract novelty of firms’ scientific
publications, innovation novelty tends to decrease after firms go public or acquire another
company. Nevertheless, the analysis of innovator mobility does not provide sufficient evidence
on whether the decline in novelty can be explained by the change in the composition of
innovators. While innovation novelty score is found to decrease on the aggregate level following
IPO and M&A activities, certain firms may still be able to exhibit growing novelty despite
undergoing an IPO and/or M&A. This section turns to individual cases of specific firms so as to
examine potential reasons behind the changes in innovation novelty around IPO and M&A
activities.

i.

Innovation Novelty Score of Cephalon Inc. around IPO
Table 23 shows the changes in innovation novelty score of Cephalon Inc. in years around

its IPO (1988-1996). Prior to its acquisition by Teva Pharmaceuticals in 2011, Cephalon was a
global pharmaceutical company founded in 1987 and went public in 1991. According to the
International Directory of Company Histories (2002), in its pre-IPO years (1987-1991),
Cephalon was almost exclusively focused on scientific research, particularly on treatments for
multiple sclerosis, strokes, and amyotrophic lateral sclerosis. Although Cephalon did not allocate
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sufficient resources to developing its sales force and navigating clinical trials, the company was
still able to raise funding from investors, secure collaboration contracts with established
pharmaceutical firms, and make decent progress on scientific discoveries. Cephalon went public
in 1991, but the market’s concern of the overvaluation of biotech stocks caused its stock price to
drop below the IPO price. As such, the company was under shareholder pressure to generate
revenues and earnings. Despite the pressure from the stock market, Cephalon continued its
research efforts in the years following the IPO. In 1993, Cephalon acquired rights to develop and
sell Provigil, a treatment for narcolepsy, from French company Laboratoire L. Lafon. In 1995,
the fourth year after its IPO, Cephalon shifted away from exclusive focus on research to sales
force development. In 2000, the company acquired product rights to Actiq, a cancer pain
treatment approved by FDA in 1998, through merging with Anesta Corporation. The company
later acquired rights to Gabitril, an epilepsy seizure treatment approved in 1997, from Abbot
Laboratories.

The changes in novelty score shown in Table 23 correspond to the crucial activities of
Cephalon during the period around its 1991 IPO. Cephalon exhibited increasing innovation
novelty in pre-IPO years due to its primary focus on R&D. Nevertheless, following its IPO, the
company was faced with significant shareholder pressure to produce solid results, leading to a
decline in innovation novelty. The novelty score recovered slightly from 1992 to 1994 because
of Cephalon’s continued R&D investments in drug development but dropped again in 1995 as
the company shifted away from exclusive research focus to building a sales force in order to
generate revenues. In addition, the nature of the post-IPO innovation efforts at Cephalon appears
to be more incremental than radical, as the rights to some of the most well-sold drugs (e.g., Actiq
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and Gabitril) were acquired from other companies rather than owned by Cephalon from the
initial development stage.

ii.

Innovation Novelty Score of Hospira Inc. around M&A
Table 24 shows the change in innovation novelty score of Hospira Inc. in years around

its 2006 M&A events (2004-2011). Hospira was created from the spin-off of the hospital
products division of Abbot Laboratories in 2004. Before its acquisition by Pfizer in 2015,
Hospira was a leading manufacturer of pharmaceutical injectables and medication management
systems. According to the International Directory of Company Histories (2014), following its
spin-off from Abbot, the company adopted an aggressive plan for increasing R&D investments.
New products were developed and launched through both internal manufacturing improvement
and acquisitions. In 2006, Hospira acquired Australian company BresaGen which developed
peptides and proteins as well as another Australian company Mayne Pharma which enabled
Hospira to become the world’s largest general injectable pharmaceuticals company. In the years
following its 2006 acquisitions, Hospira maintained its focus on research and continued to
introduce new products such as irinotecan hydrochloride (an oncology drug) and imipenemcilastatin (an antibiotic). The company also engaged in strategic collaborations such as a
partnership with Bridge Medical to improve the medication management system.

As Table 24 shows, Hospira experienced a generally increasing novelty trend postM&A, although the novelty score for firms on the aggregate level tends to decline following
M&A activities. The spin-off from Abbot in 2004 enabled Hospira to concentrate resources in
R&D spending, and the acquisition of BresaGen and Mayne Pharma in 2006 allowed Hospira to
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expand internationally. Overall, it appears that Hospira was able to maintain consistent research
momentum through a balanced mix of internal development, research collaborations, and
acquisitions over its life cycle.

iii.

Innovation Novelty Score of Eastman Chemical Company around M&A
Table 25 shows the change in innovation novelty score of Eastman Chemical Company

in years around its 1999 M&A event (1996-2004). Created as a result of the spin-off from
Eastman Kodak in 1994, Eastman Chemical is a global specialty chemical company that
produces chemicals, fibers, and plastics materials. According to the International Directory of
Company Histories (2011), Eastman Chemical focused on product innovation and globalization
in the initial years after the spin-off in order to maintain a competitive edge in the chemicals
market. In 1999, as part of its product innovation strategy, Eastman Chemical acquired Lawter
International, a manufacturer of specialty products for ink and coatings. However, due to
decreasing demand for chemicals products, Eastman was already faced with production
overcapacity by 1997 and had to initiate a restructuring process to reduce operational costs. As a
result, the company gradually shifted from product innovation to process innovation. For
instance, Eastman set up system-to-system connections with trading partners and established a
joint venture with Henderson China Holdings to launch e-commerce websites in China. In 2003,
Eastman sold off parts of its coatings, adhesives, specialty polymers, and inks (CASPI) division
which was underperforming and reduced workforce. Nevertheless, despite slightly better results
through process innovation, the chemicals industry continued to be in a downturn in the early
2000s.
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The fluctuations in innovation novelty score in Table 25 seem to align with Eastman’s
strategic decisions from 1996 to 2004. Focused on product innovation and globalization in the
1990s, the company had limited room for generating highly novel innovation due to decreasing
demand for chemicals products worldwide. As such, the company shifted from product
innovation and production capacity improvement to process innovation. The switch to a different
innovation area resulted in increasing innovation novelty, but the novelty score still dropped
around 2003 due to the continued downturn of the chemicals industry. It appears that the changes
in the novelty score of Eastman Chemical Company were more closely related to
macroeconomic patterns than to the acquisition of Lawter International in 1999.

iv.

Innovation Novelty Score of Millennium Pharmaceuticals around IPO and M&A
Table 26 shows the change in innovation novelty score of Millennium Pharmaceuticals

Inc. in years around its 1996 IPO event and 1997 M&A event (1995-2002). Founded in 1993,
Millennium Pharmaceuticals is a global pharmaceuticals company specializing in treatments for
oncology, inflammation, and metabolic diseases. According to the International Directory of
Company Histories (2002), Millennium engaged in R&D primarily through research
collaborations. In 1994, the company signed strategic alliance with Hoffmann-La Roche to
develop drugs that treat type II diabetes. In 1995, it established a joint venture with Eli Lilly to
develop treatment for atherosclerosis and collaborated with Astra AB to target inflammatory
diseases. Millennium went public in 1996 as its research efforts started to translate into tangible
results. In 1997, Millennium acquired ChemGenics Pharmaceuticals which allowed the company
to broaden its development of antibacterial drugs. In the following years, Millennium signed up
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for more strategic alliances with collaborators including Bayer AG, Bristol-Myers Squibb, and
Aventis SA. In 2001, Millennium acquired Cor Therapeutics via a stock swap and gained rights
to cardiovascular drugs.

As Table 26 shows, the innovation novelty score of Millennium Pharmaceuticals was in
a declining trend following its 1996 IPO. The company pursued an innovation strategy based
primarily on strategic collaborations and acquisitions. As such, the focus on collaborations and
acquisitions as opposed to internal drug development may have caused innovation novelty to
decline.

Overall, according to the four case studies in this section, it appears that companies which
can maintain strong R&D momentum through a balanced combination of internal development
and strategic collaborations tend to achieve higher innovation novelty following IPO and M&A
events. Nevertheless, as the Eastman Chemical case demonstrates, sometimes the changes in
innovation novelty following an IPO or M&A might be more related to fluctuations in industry
performance than to the IPO or M&A event specifically.

5. Conclusion
In this paper, I examine the change in firms’ innovation performance around IPO and
M&A events based on metrics from three modes of innovation – patents, product introductions,
and scientific publications. While scholars have primarily focused on only one innovation mode,
I consider all three modes to comprehensively measure firms’ innovative activities. To assess the
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quality of innovation, in addition to the citation count metric which has been widely used in the
literature, I also consider the abstract novelty score in the case of scientific publications in order
to conduct a more in-depth examination of the innovative content of each innovation. After
examining a variety of innovation modes and metrics, I find that innovation quantity increases
while innovation quality decreases following IPO and M&A events. The results are generally
consistent among patent-based, product-based, and publication-based metrics, and confirm with
the results from previous literature.

In addition to exploring how innovation performance varies with IPO and M&A status, I
also control for industry characteristics (sales concentration, turbulence, and geographic
concentration) and firm-level financial metrics (total assets, net income to total assets, cash to
total assets, and R&D to total assets). In general, higher sales concentration and geographic
concentration relate to lower innovation quantity (number of innovations) in post-event years
than in pre-event years, possibly due to reduced incentives to produce high quantity of
innovations when the market in post-event years is more concentrated, barriers to entry are
higher, and resources and collaborators are more reachable. However, higher sales concentration
and geographic concentration tend to correlate with higher innovation quality (novelty of
innovation) in post-event years than in pre-event years, possibly because firms have higher
capacity to focus on generating economic value from truly novel innovations when the market in
post-event years is more financially and geographically concentrated. As Feldman (1993) shows,
“innovation is found to cluster geographically in areas which contain concentrations of
specialized resources which enhance and facilitate the innovation process.” In terms of financial
metrics, firms that exhibit larger asset and cash holdings, higher profitability, and more R&D
investments are generally more innovative in terms of both quality and quantity.
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Overall, despite the ability to produce more innovations after going public or acquiring
another company, firms need to be mindful of the potential loss in innovation quality. Innovation
is a long-term task crucial to a firm’s long-term performance, but firms might be subject to
higher shareholder pressure once they go public or experience a change in the composition of
major shareholders following an M&A. As such, firms may be pressured to satisfy short-term
earnings at the expense of long-term performance. Although the study of innovator mobility in
this paper does not provide sufficient insights on whether the changes in innovation performance
around strategic events are explained by the changes in the composition of innovators, it is still
reasonable to believe that the restructuring of the talent base following strategic events can exert
substantial influence on a firm’s innovation capacity, whether positively or negatively.
Moreover, the case studies on specific firms show that firms which can maintain innovation
momentum through a balanced combination of internal development and strategic collaborations
following IPO and M&A events tend to exhibit increasing novelty score, while companies that
focus too much on generating revenues or pursue an unbalanced innovation strategy tend to
experience declines in novelty. Therefore, it would be essential for firms to develop strategies to
maintain and enhance innovation quality and avoid disruptions to innovative capacity.

6. Discussion
A. Significance
This paper could be helpful to corporate strategy researchers and experts, especially those
who focus on corporate innovation. Instead of restricting the measurement of innovation to
patent-based metrics, the paper discusses alternative sources of innovation such as new scientific
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publications and new product introductions and aims to improve the measurement of innovation
quality through textual analysis of article abstracts. By proposing a more comprehensive measure
of innovation performance, this paper could help future researchers to gain a more systematic
understanding of innovation and open up new perspectives as they explore the innovative
practices of firms and how they relate to various aspects of firm performance.
The paper could also be relevant to firms as they attempt to continuously improve their
innovation performance in order to achieve competitive advantages against their peers. For
example, the proposed innovation novelty score should help firms to more accurately assess their
innovation quality relative to their competitors. The findings on innovator mobility and the case
studies on specific firms around IPO and M&A activities may also be useful as firms make their
strategic decisions on whether to go public or engage in a merger or acquisition.

B. Limitations and Ideas for Future Work
This research contains some limitations as well. First, when analyzing the change in
innovation around M&A events, I only include M&A transactions involving public acquirers, as
most target firms would disappear following an acquisition. However, some target firms may
remain as separate subsidiaries of their corresponding acquirer firms after acquisitions, so some
patents may be assigned to the target firm rather than to the acquirer firm, despite the fact that
the innovation comes from the acquirer firm as a whole. As such, this analysis may
underestimate the innovation output following M&A events. Nevertheless, simply adding the
patents of post-acquisition target firms to the set of patents from the parent firms would not work
as the Thomson SDC database only contains M&A transactions involving public firms. Some
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public parent firms may have acquired private subsidiary firms that operate as a standalone entity
in the US patent system and do not show up in the patent database. In order to mitigate the
underestimation problem, it would be better to utilize a database that contains M&A transactions
involving both public and private firms so that private acquirers and targets are not excluded
from the analysis.
Second, the regression analyses on within-firm variations in innovation performance are
endogenous in itself and prone to self-selection bias. According to Bernstein (2015), firms may
choose to go public at a specific stage in their respective life cycle. For example, firms might be
more likely to go public when they have achieved highly novel innovations, so the regression to
measure how innovation relates to IPO status might be subject to the effect of life cycle as a
confounding variable. In addition, my results are primarily based on OLS linear regression
analysis, so I have only established relationships between innovation performance and IPO or
M&A status. In order to examine whether the post-event increase in innovation quantity and
decrease in innovation quality are indeed caused by the strategic event itself, I would need to
compare the innovation of firms that underwent the event with that of similar firms that did not.
Hence, in future work, I could follow Bernstein (2015) to compare the post-IPO innovation
performance of firms that actually went public with that of similar firms that filed for IPO but
did not go public eventually. The same method would apply to the M&A case.
Third, my calculation of the novelty score for scientific publications might also contain
algorithmic errors. Because Scopus does not contain unique identifiers for firm names, I
manually input firm names into Scopus’ web search query to download basic publication
information and then match the firm names in the downloaded data to GVKEY identifiers.
Because there might be multiple variations of a firm’s name, the matching process may be crude
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and incomplete. In addition, in order to focus on only innovative words in the abstract textmining analysis, I remove the stop words identified by the SMART information retrieval system.
Nevertheless, the removal process might not be exhaustive and there might be certain
commonly-used words or phrases that should not be considered as innovative content. In future
work, instead of applying a built-in stop-word list such as SMART, I would need to conduct an
analysis on Term Frequency–Inverse Document Frequency (TF-IDF) to investigate how
important each abstract word is to the scientific publications in my collection. In this way, I
could effectively remove words that are not novel enough in scientific research.
Fourth, I have been able to analyze the three innovation modes (patents, product
introductions, and scientific publications) separately in this paper, but the observed relationships
could be verified in the future through exploring all three innovation modes collectively to
analyze the association and causation between overall firm innovation and strategic activities.
According to Murray and Stern (2007), scientific publications tend to pre-date patent grants and
publication citations tend to decline following patent grants. Therefore, one potential way to
consolidate patents and publications is to place a higher weight on publication-based metrics
prior to patent grant and a higher weight on patent-based metrics after the patent grant. This
approach should help researchers to obtain a more comprehensive understanding of firm
innovation.
Last but not the least, as employee mobility increases and information exchange becomes
more convenient, companies have been transitioning from an internal and closed innovation
strategy to a combination of internal development and open innovation. Scholars have
demonstrated that an open innovation process facilitates innovators to adopt a solution-seeking
mindset and focus on the big picture of why an innovation is needed (Lifshitz-Assaf, Tushman,
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and Lakhani 2018). Open innovation is also found to broaden a firm’s knowledge and expertise
by enabling the firm to venture into new technological areas and strengthen existing areas that
are still insufficient (Shin et al. 2017). However, while firms may intend to source distant
knowledge through open innovation, the process of sourcing external ideas might actually
narrow their perspective as they are more likely to focus on knowledge areas that are more
familiar to them (Piezunka and Dahlander 2015).
In this research paper, I investigate how firm innovation as a whole changes around IPO
and M&A activities but do not distinguish between closed and open innovation. In order to
contribute to the field of research on open innovation, I could expand the scope of this paper by
analyzing how the performance of open innovation changes around firms’ IPO and M&A
activities. One approach would be to analyze the change in collaboration pattern around IPO and
M&A events. Following Belderbos et al. (2014), I can classify the collaborators of each patent or
scientific publication into intra-industry partners or competitors, inter-industry partners or
complementors, and universities. Then, I would explore the change in the composition of
collaborators around IPO and M&A and how the collaboration pattern relates to the quantity and
quality of open innovation. In addition, I could also calculate an “innovation openness ratio” for
each firm based on the framework proposed by Michelino et al. (2015) and examine how the
openness ratio fluctuates around IPO and M&A events. A third way of measuring open
innovation could be based on a firm’s usage of open source software in its innovative activities
(Nagle 2018). The study of how open innovation relates to IPO and M&A events should provide
insights into whether enhanced access to financial and strategic resources following an IPO or
M&A event would enable a firm to enhance the scale and quality of its open innovation efforts.
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Appendix
Table 1. Summary Statistics of Patent-IPO Dataset
This table displays summary statistics of the patent applications of firms from three years before
to five years after going public. Section A displays the distribution of patent applications across 6
major tech classes. Sections B and C show the average innovation measures during 3 years
before IPO and during 5 years after IPO, respectively. Section D lists the IPO filing, patent
applications, and patent grants by year.
Section A – Distribution of patents across 6 major tech classes

Section B – Average innovation measures during 3 years before IPO

Section C – Average innovation measures during 5 years after IPO
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Section D – IPO Filing, Patent Applications, and Patent Grants by Year
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Table 2. Within-Firm Change in Patent Count around IPO
This table shows the changes in patent count around IPO. I use the natural logarithm of the
patent count to reduce skewness in the data. To avoid any zero values, I add one to the patent
count when taking the natural logarithm. The regression in Column (1) only considers IPO status
dummies. Column (2) adds industry metrics, including sales concentration (HHI), turbulence,
and geographic concentration (EGI), as well as their interactions with post-IPO status. Column
(3) adds four additional variables on financial metrics: log total assets, net income / total assets,
cash / total assets, and R&D / total assets.
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Table 3. Within-Firm Change in Patent Quality Metrics around IPO
This table shows the changes in three patent quality metrics around IPO. I use the natural
logarithm of the citation count to reduce skewness in the data. To avoid any zero values, I add
one to the citation count when taking the natural logarithm. Column (1) shows the change in
average log citation count, Column (2) shows the change in average generality (degree to which
a patent is cited by patents from a more diverse range of technology classes), and Column (3)
shows the change in average originality (degree to which a patent is citing a broader set of
technology classes). Independent variables include IPO status dummies, industry metrics (sales
concentration HHI, turbulence, and geographic concentration EGI), and their interactions with
post-IPO status.
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Table 4. Summary Statistics of Patent-M&A Dataset
This table displays summary statistics of the patent applications of firms from three years before
to five years after M&A transactions. Section A displays the distribution of patent applications
across 6 major tech classes. Sections B and C show the average innovation measures during 3
years before M&A and during 5 years after M&A, respectively. Section D lists the M&A deals,
patent applications, and patent grants by year.
Section A – Distribution of patents across 6 major tech classes

Section B – Average innovation measures during 3 years before M&A

Section C – Average innovation measures during 5 years after M&A
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Section D – M&A Deals, Patent Applications, and Patent Grants by Year
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Table 5. Within-Firm (Acquirer) Change in Patent Count around M&A
This table shows the changes in patent count around M&A for acquirers. I use the natural
logarithm of the patent count to reduce skewness in the data. To avoid any zero values, I add one
to the patent count when taking the natural logarithm. The regression in Column (1) only
considers M&A status dummies. Column (2) adds industry metrics, including sales concentration
(HHI), turbulence, and geographic concentration (EGI), as well as their interactions with postM&A status. Column (3) adds four additional variables on financial metrics: log total assets, net
income / total assets, cash / total assets, and R&D / total assets.
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Table 6. Within-Firm (Acquirer) Change in Patent Quality Metrics around M&A
This table shows the changes in three patent quality metrics around M&A for acquirers. I use the
natural logarithm of the citation count to reduce skewness in the data. To avoid any zero values, I
add one to the citation count when taking the natural logarithm. Column (1) shows the change in
log average citation count, Column (2) shows the change in average generality (degree to which
a patent is cited by a more technologically varied array of patents), and Column (3) shows the
change in average originality (degree to which a patent is citing a broader array of technology
classes). Independent variables include M&A status dummies, industry metrics (sales
concentration HHI, turbulence, and geographic concentration EGI), and their interactions with
post-M&A status.
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Table 7. Summary Statistics of Product-M&A Dataset
This table displays summary statistics of the product introductions of firms from three years
before to five years after M&A transactions. Section A displays the distribution of product
introductions across 7 major product sectors. Sections B and C show the average innovation
measures during 3 years before M&A and during 5 years after M&A, respectively. Section D
lists the M&A deals and total product introductions by year.
Section A – Distribution of product introductions across 7 major product sectors

Section B – Average innovation measures during 3 years before M&A

Section C – Average innovation measures during 5 years after M&A
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Section D – M&A Deals and Total Product Introductions by Year
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Table 8. Within-Firm Change in Total Product Introductions around M&A
This table shows the changes in total product count around M&A for acquirers. I use the natural
logarithm of the total product count to reduce skewness in the data. To avoid any zero values, I
add one to the product count when taking the natural logarithm. The regression in Column (1)
only considers M&A status dummies. Column (2) adds industry metrics, including sales
concentration (HHI), turbulence, and geographic concentration (EGI), as well as their
interactions with post-M&A status. Column (3) adds four additional variables on financial
metrics: log total assets, net income / total assets, cash / total assets, and R&D / total assets.

54

Table 9. Within-Firm Change in Breakthrough Product Introductions around
M&A
This table shows the changes in breakthrough product count around M&A for acquirers. I use the
natural logarithm of the breakthrough product count to reduce skewness in the data. To avoid any
zero values, I add one to the product count when taking the natural logarithm. The regression in
Column (1) only considers M&A status dummies. Column (2) adds industry metrics, including
sales concentration (HHI), turbulence, and geographic concentration (EGI), as well as their
interactions with post-M&A status. Column (3) adds four additional variables on financial
metrics: log total assets, net income / total assets, cash / total assets, and R&D / total assets.
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Table 10. Summary Charts from Abstract Text-Mining
This table displays summary charts from text mining of the words in the abstracts of the
scientific articles published by firms. Section A displays the 20 most commonly-used words in
abstracts and their respective frequencies. Some words appear to be incomplete because I have
stemmed each word (removed any inflectional affixes in each word) in order to ensure that all
forms of each word have been captured. Section B shows a word cloud generated from the set of
stemmed words, with visually larger words being more common.

Section A – The 20 Most Common Words in the Abstracts of Scientific Publications
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Section B – Word Cloud
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Table 11. Summary Statistics of Publication-IPO Dataset
This table displays summary statistics of the scientific article publications of firms from three
years before to five years after IPO. Section A displays the distribution of scientific publications
across 9 major journal fields. Sections B and C show the average innovation measures during 3
years before IPO and during 5 years after IPO, respectively. Section D lists the IPO filings and
total scientific publications by year.
Section A – Distribution of scientific publications across 9 major journal fields

Section B – Average innovation measures during 3 years before IPO

Section C – Average innovation measures during 5 years after IPO
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Section D – IPO Filings and Scientific Publications by Year
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Table 12. Within-Firm Change in Publication Count around IPO
This table shows the changes in scientific publication count around IPO. I use the natural
logarithm of the publication count to reduce skewness in the data. To avoid any zero values, I
add one to the publication count when taking the natural logarithm. The regression in Column (1)
only considers IPO status dummies. Column (2) adds industry metrics, including sales
concentration (HHI), turbulence, and geographic concentration (EGI), as well as their
interactions with post-IPO status. Column (3) adds four additional variables on financial metrics:
log total assets, net income / total assets, cash / total assets, and R&D / total assets. In the output
of the regression analysis, the interaction items are omitted because they have been dropped by
the model due to rank deficiency.
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Table 13. Within-Firm Change in Collaborator Count around IPO
This table shows the changes in research collaborator count (number of collaborators/co-authors
of each paper) around IPO. I use the natural logarithm of the collaborator count to reduce
skewness in the data. To avoid any zero values, I add one to the collaborator count when taking
the natural logarithm. The regression in Column (1) only considers IPO status dummies. Column
(2) adds industry metrics, including sales concentration (HHI), turbulence, and geographic
concentration (EGI), as well as their interactions with post-IPO status. Column (3) adds four
additional variables on financial metrics: log total assets, net income / total assets, cash / total
assets, and R&D / total assets. In the output of the regression analysis, the interaction items are
omitted because they have been dropped by the model due to rank deficiency.
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Table 14. Within-Firm Change in Citation Count around IPO
This table shows the changes in average publication citation count around IPO. I use the natural
logarithm of the average citation count to reduce skewness in the data. To avoid any zero values,
I add one to the average citation count when taking the natural logarithm. The regression in
Column (1) only considers IPO status dummies. Column (2) adds industry metrics, including
sales concentration (HHI), turbulence, and geographic concentration (EGI), as well as their
interactions with post-IPO status. Column (3) adds four additional variables on financial metrics:
log total assets, net income / total assets, cash / total assets, and R&D / total assets. In the output
of the regression analysis, the interaction items are omitted because they have been dropped by
the model due to rank deficiency.
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Table 15. Within-Firm Change in Novelty Score around IPO
This table shows the changes in average novelty score around IPO. The regression in Column (1)
only considers IPO status dummies. Column (2) adds industry metrics, including sales
concentration (HHI), turbulence, and geographic concentration (EGI), as well as their
interactions with post-IPO status. Column (3) adds four additional variables on financial metrics:
log total assets, net income / total assets, cash / total assets, and R&D / total assets.
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Table 16. Summary Statistics of Publication-M&A Dataset
This table displays summary statistics of the scientific article publications of firms from three
years before to five years after M&A transactions. Section A displays the distribution of
scientific publications across 9 major journal fields. Sections B and C show the average
innovation measures during 3 years before M&A and during 5 years after M&A, respectively.
Section D lists the M&A transactions and total scientific publications by year.
Section A – Distribution of scientific publications across 9 major journal fields

Section B – Average innovation measures during 3 years before M&A

Section C – Average innovation measures during 5 years after M&A
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Section D – M&A Deals and Scientific Publications by Year
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Table 17. Within-Firm Change in Publication Count around M&A
This table shows the changes in scientific publication count around M&A. I use the natural
logarithm of the publication count to reduce skewness in the data. To avoid any zero values, I
add one to the publication count when taking the natural logarithm. The regression in Column (1)
only considers M&A status dummies. Column (2) adds industry metrics, including sales
concentration (HHI), turbulence, and geographic concentration (EGI), as well as their
interactions with post-M&A status. Column (3) adds four additional variables on financial
metrics: log total assets, net income / total assets, cash / total assets, and R&D / total assets. In
the output of the regression analysis, the interaction items are omitted because they have been
dropped by the model due to rank deficiency.
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Table 18. Within-Firm Change in Collaborator Count around M&A
This table shows the changes in research collaborator count (number of collaborators/co-authors
of each paper) around M&A. I use the natural logarithm of the collaborator count to reduce
skewness in the data. To avoid any zero values, I add one to the collaborator count when taking
the natural logarithm. The regression in Column (1) only considers M&A status dummies.
Column (2) adds industry metrics, including sales concentration (HHI), turbulence, and
geographic concentration (EGI), as well as their interactions with post-M&A status. Column (3)
adds four additional variables on financial metrics: log total assets, net income / total assets, cash
/ total assets, and R&D / total assets. In the output of the regression analysis, the interaction
items are omitted because they have been dropped by the model due to rank deficiency.
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Table 19. Within-Firm Change in Citation Count around M&A
This table shows the changes in average publication citation count around M&A. I use the
natural logarithm of the average citation count to reduce skewness in the data. To avoid any zero
values, I add one to the average citation count when taking the natural logarithm. The regression
in Column (1) only considers M&A status dummies. Column (2) adds industry metrics,
including sales concentration (HHI), turbulence, and geographic concentration (EGI), as well as
their interactions with post-M&A status. Column (3) adds four additional variables on financial
metrics: log total assets, net income / total assets, cash / total assets, and R&D / total assets. In
the output of the regression analysis, the interaction items are omitted because they have been
dropped by the model due to rank deficiency.
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Table 20. Within-Firm Change in Novelty Score around M&A
This table shows the changes in average novelty score around M&A. The regression in Column
(1) only considers M&A status dummies. Column (2) adds industry metrics, including sales
concentration (HHI), turbulence, and geographic concentration (EGI), as well as their
interactions with post-M&A status. Column (3) adds four additional variables on financial
metrics: log total assets, net income / total assets, cash / total assets, and R&D / total assets.
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Table 21. Innovator Mobility around IPO
This table displays comparisons of mean publication count, mean citation count, and mean
novelty score of three types of innovators around IPO. A stayer is an author with at least a single
paper before and after the IPO at the same firm; a leaver is an author with at least a single paper
at a sample firm before the IPO, and at least a single paper in a different company after the IPO;
a newcomer is an author that has at least a single paper after the IPO event at a sample firm, but
no papers before, and has at least a single paper at a different firm before the event. Section A
displays the comparisons between stayers and leavers during the three years before IPO. Section
B displays the comparisons between stayers and newcomers during the five years after IPO.
Section A – Stayers vs. Leavers in pre-IPO years

Section B – Stayers vs. Newcomers in post-IPO years
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Table 22. Innovator Mobility around M&A
This table displays comparisons of mean log publication count, mean log citation count, and
mean novelty score of three types of innovators around M&A. A stayer is an author with at least
a single paper before and after the M&A at the same firm; a leaver is an author with at least a
single paper at a sample firm before the M&A, and at least a single paper in a different company
after the M&A; a newcomer is an author that has at least a single paper after the M&A event at a
sample firm, but no papers before, and has at least a single paper at a different firm before the
event. Section A displays the comparisons between stayers and leavers during the three years
before M&A. Section B displays the comparisons between stayers and newcomers during the
five years after M&A.
Section A – Stayers vs. Leavers in pre-M&A years

Section B – Stayers vs. Newcomers in post-M&A years
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Table 23. Innovation Novelty Score of Cephalon Inc. around IPO
This chart shows the change in innovation novelty score of Cephalon Inc. in years around its
1991 IPO (from 1988 to 1996). The novelty score is calculated based on the average age of nonstop words in the abstract of each article by journal field. The red dashed line indicates that
Cephalon went public in year 1991.
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Table 24. Innovation Novelty Score of Hospira Inc. around M&A
This chart shows the change in innovation novelty score of Hospira Inc. in years around its 2006
M&A events (from 2004 to 2011). The novelty score is calculated based on the average age of
non-stop words in the abstract of each article by journal field. The red dashed line indicates that
Hospira acquired BresaGen Ltd. and Mayne Pharma in 2006.
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Table 25. Innovation Novelty Score of Eastman Chemical Co. around M&A
This chart shows the change in innovation novelty score of Eastman Chemical Co. in years
around its 1999 M&A event (from 1996 to 2004). The novelty score is calculated based on the
average age of non-stop words in the abstract of each article by journal field. The red dashed line
indicates that Eastman Chemical acquired Lawter International Inc. in 1999.
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Table 26. Innovation Novelty Score of Millennium Pharmaceuticals Inc. around IPO
and M&A
This chart shows the change in innovation novelty score of Millennium Pharmaceuticals Inc. in
years around its 1996 IPO event and 1997 M&A event (from 1995 to 2002). The novelty score is
calculated based on the average age of non-stop words in the abstract of each article by journal
field. The blue dashed line indicates that Millennium Pharmaceuticals went public in 1996. The
red dashed line indicates that Millennium Pharmaceuticals acquired ChemGenics
Pharmaceuticals Inc. in 1997.
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